D3 Bio announced FDA IND clearance for D3S‑003, a small‑molecule KRAS G12D inhibitor, enabling a first‑in‑human phase I study in patients with advanced solid tumors harboring KRAS G12D mutations. The IND clearance permits clinical dosing and marks a key translational step for a target historically considered hard to drug. KRAS G12D is a prevalent oncogenic driver across several tumor types; moving D3S‑003 into humans will test target engagement, safety and early signals of anti‑tumor activity. Sponsors typically design these initial trials to assess tolerability and pharmacokinetics and to identify recommended phase II doses. Investors and oncology drug‑development teams will watch for early biomarker and response readouts, which can validate continued investment in G12D‑selective chemotypes and influence competitive positioning among other KRAS‑directed programs.